Kerecis Silicone Fish-Skin Combination for Wound Healing Receives Approval from Palmetto Insurance Group
16 Julio 2024 - 7:04PM
Business Wire
60% of the Medicare population now has access to Kerecis Shield
in private doctors’ clinics
Kerecis, the company pioneering the use of sustainably sourced
fish-skin and fatty acids in cellular therapy, tissue regeneration
and protection, has received approval from Palmetto GBA for the
Kerecis Shield™ private doctors’ clinics fish-skin product range.
The approval makes the product eligible for Medicare Part B
coverage across Alabama, Georgia, North Carolina, South Carolina,
Tennessee, Virginia and West Virginia.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240716475356/en/
Kerecis Silicone Fish-Skin Combination
for Wound Healing Receives Approval from Palmetto Insurance Group
(Photo: Business Wire)
This recent approval means that 4 of the 7 insurance companies
administering Medicare plans across the US have set a fee schedule
for the Shield product line, providing improved and more timely
patient access to treatment with Kerecis medical-fish-skin
treatments. Now, 60% of the Medicare population enjoys access to
Kerecis Shield.
For physicians operating in private clinics, this means that
invoices will not need to be submitted for reimbursement, improving
efficiency by eliminating a step in the reimbursement process.
The Kerecis Shield product range for private doctors’ clinics,
announced in April 2023, integrates the Kerecis medical-fish-skin
graft with a silicone contact layer. The product range consisting
of Shield Standard, Shield Adhesive and Shield Spiral, is designed
for managing chronic and acute wounds such as diabetic foot ulcers,
pressure ulcers, vascular ulcers, post-Moh's surgical wounds, and
draining wounds.
“This additional insurance coverage for our Kerecis Shield
product line means that about 60% of Medicare patients now have
access to this latest fish-skin treatment, up from around 40%,”
said Fertram Sigurjonsson, founder and CEO of Kerecis. “200 million
Americans already have insurance coverage for our Kerecis MariGen
portfolio of medical-fish-skin products. This new coverage for our
new Kerecis Shield product allows more private clinics to provide
their patients with the new, sophisticated treatments they
require.”
About Kerecis
Kerecis was founded by Fertram Sigurjonsson to develop products
from fish skin and fatty acids for cellular therapy, tissue
regeneration and protection. When grafted onto damaged human tissue
or implanted, the patented material supports the body’s own
processes to heal and regenerate. Because no disease-transfer risk
exists between cold-water fish and humans, the Kerecis fish skin is
only gently processed and retains its similarity to human tissue.
The gentle processing preserves the skin’s original
three-dimensional structure, maintaining its inherent natural
strength, complexity and molecules (such as fatty acids). Clinical
studies have found that the Kerecis products heal wounds faster
than competing products. Kerecis is the only approved manufacturer
of medical devices containing intact fish skin globally.
Kerecis is the fastest-growing and one of the top five companies
in the U.S. biologics-skin and dermal-substitute market, according
to SmartTRAK Business Intelligence. Kerecis’ expanding product
portfolio includes SurgiBind®/SurgiClose®, which are used for
reconstructive surgery in hospital operating rooms; GraftGuide®,
which is mostly sold to burn centers; and MariGen® and Shield™,
which are sold to healthcare facilities to treat chronic wounds
such as diabetic wounds, as well as post-Moh's surgery wounds.
Kerecis is committed to the United Nations Sustainable
Development Goals. The fish skin used in Kerecis’ products derives
from wild and sustainable fish stock caught in pristine Icelandic
waters and processed with 100% renewable energy in the town of
Isafjordur, close to the Arctic Circle. Kerecis is part of
Coloplast, the leading global supplier of intimate healthcare
products. For more information, visit https://www.kerecis.com.
About Palmetto
Palmetto GBA is one of the nation's largest providers of
high-volume claims and transaction processing, contact center
operations and technical services to the federal government and
other commercial customers.
Trademarks and registered trademarks are the property of their
respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240716475356/en/
Hrannar Petursson Director of Communications +354 666 1000
hpet@kerecis.com